Neurological Malpractice and Nonmalpractice Liability

Neurologic Clinics

Volumn 28, Issue 2, 2010, Pages 441-458

  Johnston, James C ^a  

^a Barrister Sole ^*  (New Zealand)

Author keywords

Forensic neurology; Medical malpractice; Neurologic misadventures; Neurological liability

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTITHROMBOCYTIC AGENT; BARBITURIC ACID DERIVATIVE; CEPHALOSPORIN DERIVATIVE; HEPARIN; PENICILLIN G; WARFARIN;

ANGIOPLASTY; BLOOD CLOT LYSIS; CAROTID ENDARTERECTOMY; CEREBROVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL HEART DISEASE; CONGENITAL MALFORMATION; DIAGNOSTIC ERROR; DOCTOR PATIENT RELATION; DRUG CONTRAINDICATION; DRUG MEGADOSE; DRUG SAFETY; EPILEPSY; FIBRINOLYTIC THERAPY; HEADACHE; HEALTH CARE MANAGEMENT; HEART ATRIUM FIBRILLATION; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; LEGAL LIABILITY; LIP MALFORMATION; MALPRACTICE; MEDICATION ERROR; NEGLIGENCE; NEURAL TUBE DEFECT; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OROFACIAL CLEFT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROFESSIONAL STANDARD; REVIEW; RISK MANAGEMENT; STRATEGIC PLANNING; STROKE; SUBARACHNOID HEMORRHAGE; TERATOGENESIS; UROGENITAL TRACT MALFORMATION;

EXPERT TESTIMONY; HEADACHE; HUMANS; LIABILITY, LEGAL; MALPRACTICE; MENTAL COMPETENCY; NEUROLOGY;

EID: 77349086629     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2009.11.008     Document Type: Review

References (100)

1. Hunter J., Cassell-Stiga G., and Doroshow J. True risk: medical liability, malpractice insurance and health care. Americans for Insurance Reform (a project of the Center for Justice and Democracy). Available at:. http://www.insurance-reform.org Accessed August 15, 2009
2. Baker T. The medical malpractice myth (2005), Univ of Chicago Press, Chicago
3. Risk management review (Neurology). Rockville (MD): Physicians Insurers Association of America; 2008.
4. Id. at Exhibit 5.
5. Id at Exhibit 7.
6. Supra note 3 at Exhibit 5-2.
7. Supra note 3 at V and Exhibit 5.
8. Supra note 3 at Exhibit 6.
9. Supra note 3 at V.
10. Supra note 3 at Exhibit 6 for claims closed in 2007.
11. Evans R. Secondary headache disorders. Neurol Clin 22 (2004) 1-260
12. Greer D. Management of subarachnoid hemorrhage, unruptured cerebral aneurysms, and arteriovenous malformations. In: Fisher M. (Ed). Stroke III: investigation and management. Handbook of clinical neurology vol. 94, series 3 (2009), Elsevier, Amsterdam, Netherlands 1239-1249
13. van Gijn J., Kerr R.S., and Rinkel G.J. Subarachnoid hemorrhage. Lancet 369 9558 (2007) 306-318
14. Rothrock J. Headaches due to vascular disorders. Neurol Clin 22 (2004) 21-37
15. Supra note 3 at V and Exhibits 5-3, 8-9.
16. Mayer P.L., Awad I.A., Todor R., et al. Misdiagnosis of symptomatic cerebral aneurysm: prevalence and correlation with outcome at four institutions. Stroke 27 (1996) 1558-1563
17. Available at:. http://www.medlink.com Accessed August 13, 2009
18. Kelly M.E., Dodd R., and Steinberg G.K. Subarachnoid hemorrhage. In: Fisher M. (Ed). Stroke part II: clinical manifestations and pathogenesis. Handbook of clinical neurology vol. 93, series 3 (2009), Elsevier, Amsterdam, Netherlands 791-808
19. Bederson J.B., Connolly E.S., Batjer H., et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group for the Stroke Council, American Heart Association: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 40 (2009) 994-1025
20. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd edition. Cephalalgia 24 Suppl 1 (2004) 1-160
21. American Academy of Neurology. Report of the quality standards subcommittee: practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Neurology 26 55 (2000) 754-762
22. American Academy of Neurology 61st Annual Meeting. Headaches in adults, 2FC.001; acute treatment of migraine headache, 7TP.002. Seattle (WA), April 25 to May 2, 2009 (access via Marathon Multimedia Syllabi2view).
23. In: Silberstein S., Lipton R., and Dodick D. (Eds). Wolff's headache and other pain. 8th edition (2008), Oxford University Press, New York
24. Evans RW. Diagnostic testing for migraine and other primary headaches. In: Evans RW, editor. Migraine and other primary headaches. Philadelphia (PA): WB Saunders Company. Neurol Clin 2009;27(2):393-415.
25. Frishberg B., Rosenberg J., Matchar D., et al. Evidence-based guidelines in the primary care setting: neuroimaging in patients with nonacute headache. US Headache Consortium, Available at:. http://www.aan.com/professionals/practice/pdfs/g10088.pdf Accessed December 3, 2009
26. Richter v Northwest Memorial Hospital, 532 N.E. 2d 269 (Ill. App. 1988).
27. Sandrini G., Friberg L., Janig W., et al. Neuropsychological tests and neuroimaging procedures in nonacute headache: guidelines and recommendations. Eur J Neurol 11 4 (2004) 217-224
28. Available at:. http://www.cdc.gov Accessed August 10, 2009
29. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
30. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995) 1017-1025
31. Hacke W., Kaste M., Fieschi C., et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous altepase in acute ischemic stroke (ECASS II). Lancet 352 (1998) 1245-1251
32. Marler J.R., Tilley B.C., Lu M., et al. Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke Study. Neurology 55 (2000) 1649-1655
33. Clark W.M., Wissman S., Albers G.W., et al. Recombinant tissue-type plasminogen activator (altepase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. JAMA 282 (1999) 2019-2026
34. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
35. Hacke W., Kaste M., Bluhmki E., et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359 (2008) 1317-1329
36. del Zoppo G.J., Saver J.L., Jauch E.C., et al. American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 40 (2009) 2945-2948
37. American Academy of Neurology. Report of the quality standards subcommittee: practice advisory: thrombolytic therapy for acute ischemic stroke (summary statement). 1996 (Reaffirmed February 18, 2003).
38. Adams H.P., del Zoppo G.J., Alberts M.J., et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an education tool for neurologists. Stroke 38 (2007) 1655-1711 [Erratum: Stroke 2007;38(6):e38, 2007;38(9):e96]
39. Levine S.R., Adamowicz D., and Johnston K.C. Primary stroke center certification. Continuum 14 6 (2008) 98-116
40. Adams, Harold P., Brott T., et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 34 (2003) 1056-1083
41. Schellinger P., Kohrmann M., and Hacke W. Thrombolytic therapy for acute stroke. In: Fisher M. (Ed). Stroke III: investigation and management. Handbook of clinical neurology vol. 94, series 3 (2009), Elsevier, Amsterdam, Netherlands 1155-1193
42. Backlund v University of Washington, 975 P.2d 950 (1999).
43. American Academy of Neurology. Consent issues in the management of cerebrovascular diseases: a position paper of the American Academy of Neurology Ethics and Humanities Subcommittee. Neurology 53 (1999) 9-11
44. Canterbury v Spence, 464 F.2d 772 (D.C. Cir. 1972), cert. denied, 408 U.S. 1064 (1974).
45. Coull B.M., Williams L.S., Goldstein L.B., et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association). Neurology 59 (2002) 13-22 (Reaffirmed August 2, 2008)
46. Schwartz N.E., Diener H., and Albers G.W. Antithrombotic agents for stroke prevention. In: Fisher M. (Ed). Stroke III: investigation and management. Handbook of clinical neurology vol. 94, series 3 (2009), Elsevier, Amsterdam, Netherlands 1277-1294
47. English J., and Smith W. Cardio-embolic stroke. In: Fisher M. (Ed). Stroke II: clinical manifestations and pathogenesis. Handbook of clinical neurology vol. 93, series 3 (2009), Elsevier, Amsterdam, Netherlands 719-749
48. Sloan M.A. Use of anticoagulant agents for stroke prevention. Continuum 11 4 (2005) 97-127
49. Freeman W.D., and Aguilar M.I. Stroke prevention in atrial fibrillation and other major cardiac sources of embolism. Neurol Clin 26 (2008) 1129-1160
50. American Academy of Neurology. Report of the quality standards subcommittee: practice parameter: stroke prevention in patients with nonvalvular atrial fibrillation. Neurology 51 (1998) 671-673
51. American Academy of Neurology 61st Annual Meeting. Neurology update i: stroke, 3FC.002. Seattle (WA), April 25 to May 2, 2009.
52. Rothwell P. Carotid endarterectomy, stenting, and other prophylactic interventions. In: Fischer M. (Ed). Stroke III: investigation and management. Handbook of clinical neurology vol. 94, series 3 (2009), Elsevier, Amsterdam, Netherlands 1295-1325
53. Chaturvedi S., Bruno A., Feasby T., et al. Carotid endarterectomy: an evidence based review: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 65 (2005) 794-801 (Reaffirmed February 9, 2008).
54. Easton D., Saver J., Albers G., et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 40 (2009) 2276-2293
55. Fairhead J., Mehta Z., and Rothwell P. Population-based study of delays in carotid imaging and surgery and the risk of recurrent stroke. Neurology 65 3 (2005) 371-375
56. American Academy of Neurology 61st Annual Meeting. Update on endovascular treatment of cerebrovascular diseases, 7AC.005. Seattle (WA), April 25 to May 2, 2009.
57. Browne R., and Holmes G. Epilepsy. N Engl J Med 344 (2001) 1145-1151
58. In: Engel J., and Pedley T. (Eds). Epilepsy: a comprehensive textbook. 2nd edition (2008), Lippincott-Raven Publishers, Philadelphia
59. Bortz J. Neuropsychiatric and memory issues in epilepsy. Mayo Clin Proc 78 (2003) 781-787
60. Krumholz A., Wiebe S., Gronseth G., et al. Practice parameter: evaluating an apparent unprovoked first seizure in adults (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 69 (2007) 1996-2007
61. Available at:. http://www.efa.org Accessed August 11, 2009
62. Tarasoff v Regents of the University of California, 551 P.32d 334 (Cal. 1976).
63. Harden v Dalrymple 883 F.Supp. 963 (D Del. 1995). Cf. Praesel v. Johnson 41 Tex. Super. Ct. J. 630 (1998).
64. Hirtz D., Thurman D., Gwinn-Hardy K., et al. How common are the common neurological disorders?. Neurology 68 (2007) 326-337
65. Morrow J., Russell A., Guthrie E., et al. Malformations risks of antiepileptic drugs in pregnancy: a prospective study from the UK epilepsy and pregnancy register. J Neurol Neurosurg Psychiatr 77 (2006) 193-198
66. Holmes L., Harvey E., Coull B., et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 344 15 (2001) 1132-1138
67. American Academy of Neurology. Practice parameter update: management issues for women with epilepsy: focus on pregnancy (an evidence based review): teratogenesis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 73 (2009) 133-141
68. Wyszynski D., Nambisan M., Survet T., et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64 (2005) 961-965
69. American Academy of Neurology. Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence based review): obstetrical complications and change in seizure frequency. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 73 (2009) 126-132
70. American Academy of Neurology. Practice parameter update: management issues for women with epilepsy: focus on pregnancy (an evidence based review): vitamin K, folic acid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 73 (2009) 142-149
71. Beresford H.R. Neurology and the law: private litigation and public policy (1998), F.A. Davis Co, Philadelphia
72. Miles J. Health care and antitrust law: principles and practice (2009), West Publishing, Eagan (MN)
73. American Bar Association, health law section. 7th National institute on civil false claims act and qui tam enforcement, 2008.
74. American Health Lawyers Association. Health law practice guide. 2nd edition (2009), West Publishing, Eagan (MN)
75. Boumil M., and Sharpe D. Boumil and Sharpe's liability in medicine and public health (American Casebook Series) (2004), West Publishing, Eagan (MN)
76. Rozovsky F., Giles C., and Kadzielski M. Health care credentialing: a guide to innovative practices (2009), Wolters Kluwer: Aspen Publishers, New York
77. Rozovsky F. Consent to treatment: a practical guide. 4th edition (2008), Wolters Kluwer: Aspen Publishers, New York
78. Boyle L. HIPAA: a guide to health care privacy and security law (2008), Wolters Kluwer: Aspen Publishers, New York
79. Shandell R., and Smith P. Securing the medical expert. In: Shandell R., and Smith P. (Eds). The preparation and trial of medical malpractice cases (2008), Law Journal Press, New York 7-1 to 7-24
80. Freemon F. The origin of the medical expert witness. J Legal Med 22 (2001) 349-373
81. Matson J., Daou S., and Soper J. Effective expert witnessing: practices for the 21st century. 4th edition (2004), CRC Press, New York
82. McAbee G. Improper expert witness testimony: existing and proposed mechanisms of oversight. J Leg Med 19 (1998) 257-272
83. Safran A., Skydell B., and Ropper S. Expert witness testimony in neurology: Massachusetts experience 1980-1990. Neurol Chronicle 44 (1992) 2477-2484
84. Holtz S. The neurologist as an expert witness. AAN Education Program Syllabus 7DS.003 (2002).
85. Hanson R. Witness immunity under attack: disarming hired guns. Wake Forest Law Rev 31 (1996) 497
86. Aufrichtig v Lowell, 650 N.E.2d 401 (N.Y. 1995).
87. Butz v Economou, 438 U.S. 478 (1978).
88. Restatement (Second) of Torts §588.
89. Marrogi v Howard, 805 So.2d 1118 (La. 2002).
90. Gustafson v Mazer, 54 P.3d 743 (2002).
91. Brennan M., Dilenschneider D., Levin M., et al. Finding and researching experts and their testimony. Available at:. http://www.expertwitnesswhitepaper.com Accessed August 13, 2009
92. Hite C., and Taylor R. Spoliation of evidence in state and federal courts in Virginia. J of Civil Litigation XIX (2007) 391-405
93. Weintraub M. Expert witness testimony. Neurol Clin 17 (1999) 363-369
94. Cohen F. The expert medical witness in legal perspective. J Legal Med 25 (2004) 185-209
95. Williams M., Mackin G., Beresford H., et al. American Academy of Neurology qualifications and guidelines for the physician expert witness. Neurology 66 (2006) 13-14
96. §6.4 Code of Professional Conduct, American Academy of Neurology Professional Association 2008.
97. Available at:. http://www.aan.com/go/disciplinary Accessed August 12, 2009
98. Williams M, Nelson S. Impeccable or impeachable? Guidance for physician expert witnesses. AAN Education Program Syllabus 5PC.002 (2009).
99. American Board of Psychiatry and Neurology: General information and board policies, §B.4. revocation of certificates, 2009.
100. Austin v American Association of Neurological Surgeons, 253 F.3d 967 (7th Cir. 2001).